Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
Quest Diagnostics, a provider of diagnostic information services, announced that City of Hope is implementing Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian, and prostate cancer.
